Evaxion Biotech A/S (EVAX)
USD 1.36
(-9.93%)
USD 1.36
(-9.93%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.71 Million | -25.77 Million | -21.93 Million | -12.43 Million | -7.02 Million | -1.99 Million |
| Net Income | -22.15 Million | -23.16 Million | -24.53 Million | -15.01 Million | -11.19 Million | -5.53 Million |
| Depreciation & Amortization | 615.94 Thousand | 571 Thousand | 344 Thousand | 105 Thousand | 81 Thousand | 74 Thousand |
| Deferred income taxes | -984 Thousand | -998 Thousand | -190 Thousand | -2.06 Million | -825 Thousand | -735 Thousand |
| Stock-based compensation | 479 Thousand | 942 Thousand | 1.37 Million | 3.4 Million | 2.36 Million | 2.06 Million |
| Change in working capital | 1.56 Million | -2.87 Million | 1.23 Million | 215 Thousand | 566 Thousand | 981 Thousand |
| Other non-cash items | 2.76 Million | -243 Thousand | -171 Thousand | 919 Thousand | 1.98 Million | 1.15 Million |
| Investing Cash Flow | -93.14 Thousand | -268 Thousand | -1.33 Million | -393 Thousand | -61 Thousand | 6000.00 |
| Investments in PPE | -87.13 Thousand | -292 Thousand | -1.36 Million | -393 Thousand | -61 Thousand | -7000.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -6009.24 | - | - | - | - | - |
| Sales/Maturities of investments | - | 24.01 Thousand | 29.95 Thousand | - | - | - |
| Other Investing Activities | -0.76 | -13.00 | 48.00 | -244 Thousand | -7000.00 | 13 Thousand |
| Financing Cash Flow | 10.7 Million | 7.85 Million | 49.8 Million | 8.81 Million | 9.5 Million | 9.02 Million |
| Debt repayment | -306.47 Thousand | -7.42 Million | -289 Thousand | -74 Thousand | -73 Thousand | -63 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -13 Thousand | - |
| Common Stock Issuance | 11.34 Million | 428.23 Thousand | 53.85 Million | 9.02 Million | 9.44 Million | 1.09 Million |
| Other Financing Activities | -432 Thousand | 428 Thousand | -3.76 Million | -128 Thousand | 317 Thousand | 7.99 Million |
| Accounts receivables | 1.1 Million | -1.48 Million | 1.86 Million | -2.51 Million | -337 Thousand | 443 Thousand |
| Accounts payables | 502.77 Thousand | -599 Thousand | -647 Thousand | 1.79 Million | 507 Thousand | 79 Thousand |
| Inventory | 1.00 | 1.48 Million | -1.86 Million | 2.51 Million | 403 Thousand | 446 Thousand |
| Other working capital | -47.07 Thousand | -2.27 Million | 1.88 Million | -1.58 Million | -7000.00 | 13 Thousand |
| Cash at beginning of period | 13.18 Million | 32.16 Million | 5.83 Million | 9.55 Million | 7.43 Million | 468 Thousand |
| Cash at end of period | 5.58 Million | 13.18 Million | 32.16 Million | 5.83 Million | 9.55 Million | 7.43 Million |
| Capital Expenditure | -87.13 Thousand | -292 Thousand | -1.36 Million | -393 Thousand | -61 Thousand | -7000.00 |
| Effect of forex changes on cash | -508 Thousand | -793 Thousand | -210 Thousand | 288 Thousand | -295 Thousand | -77 Thousand |
| Net cash flow / Change in cash | -7.6 Million | -18.98 Million | 26.33 Million | -3.72 Million | 2.12 Million | 6.96 Million |
| Free Cash Flow | -17.8 Million | -26.06 Million | -23.29 Million | -12.83 Million | -7.08 Million | -1.99 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 1.19 Million | -22.15 Million | -4.52 Million | -5.67 Million | -5.68 Million | -6.24 Million |
| Depreciation & Amortization | - | 615.94 Thousand | 115 Thousand | 200 Thousand | - | - |
| Deferred income taxes | - | -984 Thousand | - | - | - | - |
| Stock-based compensation | - | 479 Thousand | -21 Thousand | 100 Thousand | - | - |
| Change in working capital | - | 1.56 Million | 904 Thousand | 707 Thousand | - | - |
| Other non-cash items | -1.19 Million | 2.76 Million | 1.51 Million | 281 Thousand | 5.68 Million | 6.24 Million |
| Investing Cash Flow | - | -93.14 Thousand | 1000.00 | -65 Thousand | - | - |
| Investments in PPE | - | -87.13 Thousand | 1000.00 | -65 Thousand | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -6009.24 | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | -0.76 | - | - | - | - |
| Financing Cash Flow | - | 10.7 Million | 5.25 Million | 96 Thousand | - | - |
| Debt repayment | - | -306.47 Thousand | -118 Thousand | -119 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 11.34 Million | - | - | - | - |
| Other Financing Activities | - | -432 Thousand | 5.37 Million | 215 Thousand | - | - |
| Accounts receivables | - | 1.1 Million | 707 Thousand | 800 Thousand | - | - |
| Accounts payables | - | 502.77 Thousand | - | - | - | - |
| Inventory | - | 1.00 | - | - | - | - |
| Other working capital | - | -47.07 Thousand | 197 Thousand | -93 Thousand | - | - |
| Cash at beginning of period | 5.58 Million | 13.18 Million | 2.6 Million | 7.11 Million | 10.24 Million | 13.18 Million |
| Cash at end of period | 5.58 Million | 5.58 Million | 5.58 Million | 2.6 Million | 7.11 Million | 10.24 Million |
| Capital Expenditure | - | -87.13 Thousand | 1000.00 | -65 Thousand | - | - |
| Effect of forex changes on cash | - | -508 Thousand | -274 Thousand | -154 Thousand | - | - |
| Net cash flow / Change in cash | - | -7.6 Million | 2.97 Million | -4.51 Million | -3.12 Million | -2.94 Million |
| Free Cash Flow | - | -17.8 Million | -2 Million | -4.45 Million | - | - |
TLO
JHS
ULTRACEMCO
GOKULAGRO
TC
EXPLEOSOL